Δ17-6-keto Prostaglandin F1α (Δ17-6-keto PGF1α), a cyclooxygenase (COX) metabolite produced from eicosapentaenoic acid (EPA) in a variety of tissues including seminal vesicles, lungs, polymorphonuclear leukocytes, and ocular tissues, alongside other 3-series COX products from EPA such as PGF3α, PGE3, and thromboxane B3, is potentially linked to a lower occurrence of glaucoma in individuals consuming a marine-rich (EPA-rich) diet.
1a,1b-Dihomo Prostaglandin F2α (1a,1b-dihomo PGF2α), a hypothetical product of adrenic acid in the COX pathway, is predominantly synthesized in the renal medulla, reflecting the selective distribution of adrenic acid in this region.
15(R)-15-methyl PGF2α, a metabolically stable analog of PGF2α, is an inactive, prodrug PGF agonist intended for activation by gastric acid through oral administration. This transformation involves acid-catalyzed epimerization that converts 15(R)-15-methyl PGF2α into its active counterpart, the 15(S)-isomer. Upon conversion, the 15(S)-isomer has been shown to induce luteolysis in rhesus monkeys following an approximately 12 mg animal dosage, a response not observed with the 15(R)-isomer.